Advances in the prediction of coronary in-stent restenosis by blood cell parameters

Home > Archive>Volume 29, Issue 2, 2021 >179-184

Advances in the prediction of coronary in-stent restenosis by blood cell parameters
DOI:
                        
                    
CSTR:
                        
                    
Author:
                        JIANG Nan1,2JIANG Nan
Dalian Medical University, Dalian, Liaoning 116000, China;Department of Cardiovascular Medcine, Northern Jiangsu Peoples Hospital, Yangzhou, Jiangsu 225000, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
GU Guangming3GU Guangming
Department of Cardiovascular Medcine, Henan Provincial Peoples Hospital, Zhengzhou, Henan 450003, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
XIE Yong2XIE Yong
Department of Cardiovascular Medcine, Northern Jiangsu Peoples Hospital, Yangzhou, Jiangsu 225000, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:1.Dalian Medical University, Dalian, Liaoning 116000, China;2.Department of Cardiovascular Medcine, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu 225000, China;3.Department of Cardiovascular Medcine, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, China)
Clc Number:
Fund Project:

Article

Figures

Metrics

Reference [47]

Cited by

Materials

Comments

Reference

[1] Kokkinidis DG, Waldo SW, Armstrong EJ.Treatment of coronary artery in-stent restenosis.Expert Rev Cardiovasc Ther, 7,5(3):191-202.

[2] Mehran R, Dangas G, Abizaid AS, et al.Angiographic patterns of in-stent restenosis:classification and implications for long-term outcome.Circulation, 9,0(18):1872-1878.

[3] Pleva L, Kukla P, Hlimomaz O.Treatment of coronary in-stent restenosis:a systematic review.J Geriatr Cardiol, 8,5(2):173-184.

[4] Bhat TM, Afari ME, Garcia LA.Neutrophil lymphocyte ratio in peripheral vascular disease:a review.Expert Rev Cardiovasc Ther, 6,4(7):871-875.

[5] Fiechter M, Ghadri JR, Jaguszewski M, et al.Impact of inflammation on adverse cardiovascular events in patients with acute coronary syndromes.J Cardiovasc Med (Hagerstown), 3,4(11):807-814.

[6] Xu N, Zhang J, Li M, et al.Incidence and classification of neointimal proliferation and in-stent restenosis in post-stenting patients at 1-year interval:findings from non-invasive coronary computed tomography angiography.Eur J Radiol, 4,3(10):1816-1821.

[7] Tanaka H, Sukhova GK, Swanson SJ, et al.Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury.Circulation, 3,8(4 Pt 1):1788-1803.

[8] Niccoli G, Montone RA, Sabato V, et al.Role of allergic inflammatory cells in coronary artery disease.Circulation, 8,8(16):1736-1748.

[9] Gencbay M.Do pre-procedural laboratory parameters predict drug-eluting stent restenosis?.Turk Kardiyol Dern Ars, 5,3(5):417-419.

[10] Acet H, ErtasF, Akil MA, et al.Relationship between hematologic indices and global registry of acute coronary events risk score in patients with ST-segment elevation myocardial infarction.Clin Appl Thromb Hemost, 6,2(1):60-68.

[11] Cildag MB, Cildag S, Koseoglu O .The relationship between neutrophil-lymphocyte ratio and primary patency of percutaneous transluminal angioplasty in hemodialysis arteriovenous fistula stenosis when using conventional and drug-eluting balloons.Cardiovasc Intervent Radiol, 6,9(12):1702-1707.

[12] Balta S, Ozturk C, Balta I, et al.The neutrophil-lymphocyte ratio and inflammation.Angiology, 6,7(3):298-299.

[13] Spark JI, Sarveswaran J, Blest N, et al.An elevated neutrophil-lymphocyte ratio independently predicts mortality in chronic critical limb ischemia.J Vasc Surg, 0,2(3):632-636.

[14] Baita S, Celik T, Mikhailids DP, et al.The relation between atherosclerosis and the neutrophil-lymphocyte ratio.Clin Appl Thromb Hemost, 6,2(5):405-411.

[15] Gabbasov Z, Kozlov S, Byazrova S, et al.Blood level of CD45+ platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease.Wien Klin Wochenschr, 6,8(23-24):898-905.

[16] Li C, Shen Y, Xu R, et al.Evaluation of preprocedural laboratory parameters as predictors of drug-eluting stent restenosis in coronary chronic total occlusion lesions.Angiology, 9,7(30):272-278.

[17] Balli M, Tasolar H, Cetin M, et al.Use of the neutrophil to lymphocyte ratio for prediction of in-stent restenosis in bifurcation lesions.Eur Rev Med Pharmacol Sci, 5,9(10):1866-1873.

[18] Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, et al.Plasma levels of C-reactive protein after coronary stent implantation.Eur Heart J, 0,1(11):52-58.

[19] Hsieh I C, Chen CC, Hsieh MJ, et al.Prognostic impact of 9-month high-sensitivity C-reactive protein levels on long-term clinical outcomes and in-stent restenosis in patients at 9 months after drug-eluting stent implantation.PLoS One, 5,0(9):1-12.

[20] Mincu RI, Janosi RA, Vinereanu D, et al.Preprocedural C-reactive protein predicts outcomes after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction:a systematic Meta-analysis.Sci Rep, 7,1(7):1-10.

[21] Nikolsky E, Ggrines CL, Cox DA, et al.Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial).Am J Cardiol, 7,9(8):1055-1061.

[22] Zouridakis EG, Garcia-Moll X, Kaski JC.Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris.Am J Cardiol, 0,6(4):449-451.

[23] Akboga MK, Canpolat U, Yayla C, et al.Association of platelet to lymphocyte ratio with inflammation and severity of coronary atherosclerosis in patients with stable coronary artery disease.Angiology, 6,7(1):89-95.

[24] Cho KI, AnnSH, Singh GB, et al.Combined usefulness of the platelet-to-lymphocyte ratio and the neutrophil-to-lymphocyte ratio in predicting the long-term adverse events in patients who have undergone percutaneous coronary intervention with a drug-eluting stent.PLoS One, 5,0(7):1-9.

[25] Yilmaz S, Sen F, Unal S, et al.Usefulness of the platelet-to-lymphocyte ratio in predicting bare-metal stent restenosis.Scand Cardiovasc J, 5,9(1):39-44.

[26] Li C, Zhang F, Shen Y, et al.Impact of neutrophil to lymphocyte ratio (NLR) index and its periprocedural change (NLRΔ) for percutaneous coronary intervention in patients with chronic total occlusion.Angiology, 7,8(7):640-646.

[27] Isik T, Uyarel H, Tanboga IH, et al. Relation of red cell distribution width with the presence, severity, and complexity of coronary artery disease[J]. Coron Artery Dis, 2012, 23(1): 51 56.

[28] Weiss G, Goodnough LT. Anemia of chronic disease[J]. N Engl J Med, 2005, 352(10): 1011 1023.

[29] Yildiz A, Tekiner F, Karakurt A, et al. Preprocedural red blood cell distribution width predicts bare metal stent restenosis[J]. Coron Artery Dis, 2014, 25(6): 469 473.

[30] Kurtul A, Murat SN, Yarliogues M, et al. The association of red cell distribution width with in stent restenosis in patients with stable coronary artery disease[J]. Platelets, 2015, 26(1): 48 52.

[31] Zhao K, Li YJ, Gao S. Role of red blood cell distribution in predicting drug eluting stent restenosis in patients with stable angina pectoris after coronary stenting[J]. Coron Artery Dis, 2015, 26(3): 220 224.

[32] Chandraskar B, Tanguay JF. Platelets and restenosis[J]. J Am Coll Cardiol, 2000, 35(3): 555 562.

[33] Yi N, Chen SY, Ma A, et al. Tunicamycin inhibits PDGF BB induced proliferation and migration of vascular smooth muscle cells through induction of HO 1[J]. Anat Rec (Hoboken), 2012, 295(9): 1462 1472.

[34] Sreeramkumar V, Adrover JM, Ballesteros I, et al. Neutrophils scan for activated platelets to initiate inflammation[J]. Science, 2014, 346(6214): 1234 1238.

[35] Fuster V, Falk E, Fallon JT, et al. The three processes leading to post PTCA restenosis: dependence on the lesion substrate[J]. Thromb Haemost, 1995, 74(1): 552 559.

[36] Guthikonda S, Lev EI, Patel R, et al. Reticulated platelets and uninhibited COX 1 and COX 2 decrease the antiplatelet effects of aspirin[J]. J Thromb Haemost, 2007, 5(3): 490 496.

[37] Choi DH, Kang SH, Song H. Mean platelet volume:a potential biomarker of the risk and prognosis of heart disease[J]. Korean J Intern Med, 2016, 31(6): 1009 1017.

[38] Choi DH, Kobayashi Y, Nishi T, et al. Combination of mean platelet volume and neutrophil to lymphocyte ratio predicts long term major adverse cardiovascular events after percutaneous coronary intervention[J]. Angiology, 2019, 70(4): 345 351.

[39] Dai Z, Gao J, Li S, et al. Mean platelet volume as a predictor for restenosis after carotid angioplasty and stenting[J]. Stroke, 2018, 49(4): 872 876.

[40] Yang A, Pizzulli L, Luderitz B. Mean platelet volume as marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris[J]. Thromb Res, 2006, 117(4): 371 377.

[41] Norgaz T, Hobikoglu G, Aksu H, et al. The relationship between preprocedural platelet size and subsequent in stent restenosis[J]. Acta Cardiol, 2004, 59(4): 391 395.

[42] Huczek Z, Kochman J, Filipak KJ, et al. Mean platelet volume on admission predicts impaired reperfusion and long term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention[J]. J Am Coll Cardiol, 2005, 46(2): 284 290.

[43] Rechcinski T, Jasinska A, Forys J, et al. Prognostic value of platelet indices after acute myocardial infarction treated with primary percutaneous coronary intervention[J]. Cardiol J, 2013, 20(5): 491 498.

[44] Ege MR, Guray U, Guray Y, et al. Platelet distribution width and saphenous vein disease in patients after CABG. Association with graft occlusion[J]. Herz, 2013, 38(2): 197201.

[45] Vatankulu MA, Sonmez O, Eertas G, et al. A new parameter predicting chronic total occlusion of coronary arteries: platelet distribution width[J]. Angiology, 2014, 65(1): 6064.

[46] Cetin M, Bakirci EM, Baysal LE, et al. Increased platelet distribution width is associated with ST segment elevation myocardial infarction and thrombolysis failure[J]. Angiology, 2014, 65(8): 737743.

[47] Hu CP, Du Y, Zhu Y, et al. Platelet distribution width on admission predicts instent restenosis in patients with coronary artery disease and type 2 diabetes mellitus treated with percutaneous coronary intervention[J]. Chin Med J (Engl), 2018, 131(7): 757763.

Get Citation

JIANG Nan, GU Guangming, XIE Yong. Advances in the prediction of coronary in-stent restenosis by blood cell parameters[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2021,29(2):179-184.

Copy

Article Metrics

Abstract:541
PDF: 652
HTML: 0
Cited by: 0

History

Received:November 06,2019
Revised:February 14,2020
Adopted:
Online: February 03,2021
Published:

Policies & Instructions

Get Citation

Share

Article Metrics

History

Article QR Code